DSIP vs Semax

Overview

DSIP (Delta Sleep-Inducing Peptide) and Semax are both neuropeptides studied for their effects on the central nervous system, but they have entirely different applications. DSIP is primarily researched for sleep and stress modulation, while Semax is a Russian-developed nootropic and neuroprotective agent. Neither is FDA-approved, but Semax has regulatory approval in Russia for cognitive and neurological conditions.

Key Facts

Aspect	DSIP	Semax
Full Name	Delta Sleep-Inducing Peptide	Semax (synthetic ACTH fragment)
Structure	9 amino acids	7 amino acids
Sequence	Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu	Met-Glu-His-Phe-Pro-Gly-Pro
Primary Use	Sleep/stress	Cognitive/neuroprotection
FDA Status	Not approved	Not approved
Russian Approval	No	Yes

Discovery and Development

Aspect	DSIP	Semax
Discovery	1977 (Switzerland)	1980s (Russia)
Origin	Isolated from rabbit brain	Synthetic ACTH(4-7) + PGP
Developer	Monnier & Schoenenberger	Institute of Molecular Genetics
Development	Academic research	Clinical development (Russia)

Primary Applications

Factor	DSIP	Semax
Main Use	Sleep regulation	Cognitive enhancement
Secondary Uses	Stress, withdrawal	Neuroprotection, stroke
Research Focus	Sleep disorders	Brain function
Approved For	Nothing	Cognitive/neurological (Russia)

Mechanism Comparison

Aspect	DSIP	Semax
Primary Action	Sleep promotion	BDNF upregulation
Receptor	Multiple/unclear	Melanocortin (partial)
CNS Effect	Sleep architecture	Neuroprotection
Hormone Effects	ACTH/cortisol modulation	ACTH-derivative

DSIP Mechanisms

1. Sleep Effects

   • Promotes delta wave sleep
   • Modulates sleep architecture
   • May affect circadian rhythm
   • Mechanism not fully characterized

2. Stress Modulation

   • Reduces ACTH/cortisol
   • Anti-stress effects proposed
   • May affect HPA axis
   • Withdrawal support (studied)

3. Other Effects

   • Analgesic properties (some studies)
   • Antioxidant activity (proposed)
   • General neuroprotective claims

Semax Mechanisms

1. BDNF Upregulation

   • Well-documented increase
   • NGF, GDNF also elevated
   • Neurotrophin support
   • Neuroprotective

2. Melanocortin Activity

   • MC3/MC4 receptor effects
   • Anti-inflammatory
   • Neuroprotective signaling

3. Cognitive Enhancement

   • Attention improvement (Russian studies)
   • Memory support
   • Stroke recovery (approved indication)

Evidence Quality

Factor	DSIP	Semax
Human Sleep Studies	Limited	N/A
Human Cognitive Studies	N/A	Russian trials
Mechanism Studies	Partial	Good
Western Validation	Very limited	Growing
Overall Evidence	Low	Low-Moderate

DSIP Research Status

Study Type	Availability	Quality
Sleep studies	Few	Variable
Mechanism	Incomplete	Low
Stress/withdrawal	Some	Low
Western replication	Limited	Low

Semax Research Status

Study Type	Availability	Quality
BDNF studies	Multiple	Moderate
Cognitive trials	Russian	Low-Moderate
Stroke studies	Russian	Low-Moderate
Western research	Growing	Moderate

Clinical Applications

DSIP Research Applications

Area	Evidence
Sleep disorders	Limited preclinical
Stress-related	Some studies
Withdrawal support	Some interest
Pain modulation	Limited

Semax Approved Uses (Russia)

Indication	Status
Cognitive impairment	Approved
Stroke recovery	Approved
Optic nerve disorders	Approved
Intellectual fatigue	Approved

Administration

Aspect	DSIP	Semax
Route	Injection (research)	Intranasal
Convenience	Requires injection	Nasal drops

Administration Convenience

Factor	DSIP	Semax
Self-administration	Difficult	Easy
Non-invasive	No	Yes
Compliance	Harder	Easier
Stability	Variable	Good

Side Effect Profiles

DSIP

Effect	Notes
Safety data	Very limited
Reported effects	Generally mild in studies
Long-term	Unknown
Human experience	Minimal

Semax

Effect	Frequency	Notes
Nasal irritation	Occasional	Mild
Hair changes	Reported	Chronic use, anecdotal
Generally well-tolerated	Yes	Russian clinical experience

Use Case Comparison

DSIP Would Be For

Candidate	Rationale
Sleep research	Primary application
Stress research	Proposed effects
Experimental	Very early stage

Semax Would Be For

Candidate	Rationale
Cognitive support	Primary indication
Neuroprotection research	BDNF effects
Stroke recovery	Russian approval
Nootropic interest	Established use (Russia)

Regulatory Status

Aspect	DSIP	Semax
FDA	Not approved	Not approved
Russia	Not approved	Approved
Ukraine	Not approved	Approved
Western Status	Research chemical	Research chemical

Scientific Interest

DSIP Research

Factor	Status
Academic interest	Low (currently)
Publications	Limited
Mechanism clarity	Poor
Development path	None

Semax Research

Factor	Status
Academic interest	Growing
Publications	Increasing
Mechanism clarity	Moderate
Development path	Established (Russia)

Summary

Factor	DSIP	Semax
Primary Application	Sleep	Cognitive
Structure	9 amino acids	7 amino acids
Route	Injection	Intranasal
BDNF Effect	Not primary	Well-documented
Regulatory Status	None	Russia approved
Evidence Level	Moderate	Moderate
Western Interest	Limited	Growing

Key Takeaways

1. Different applications: DSIP for sleep; Semax for cognition
2. Semax has regulatory approval: Approved in Russia; DSIP nowhere
3. Different administration: DSIP injection vs Semax nasal drops
4. Semax mechanism clearer: BDNF upregulation well-documented
5. DSIP mechanism unclear: Sleep effects not fully characterized
6. Semax has more evidence: More research and clinical experience
7. Neither FDA-approved: Both are research chemicals in West
8. Convenience differs: Semax nasal drops easier than DSIP injections

---

This comparison is for educational purposes only. Semax is approved in Russia but not by Western regulators. DSIP is not approved anywhere. Both are research chemicals in Western countries.